ZYUS (TSX.V: ZYUS) is a life sciences company focused on the global development and commercialization of novel cannabinoid-based pharmaceutical drug product candidates for pain management. Through scientific discovery and clinical research, ZYUS is committed to advancing non-opioid-based pharmaceutical products. Our active engagement in intellectual property activities aims to safeguard these novel therapies, with the goal of developing them into regulatory approved, prescription medications that will redefine the standard of care in pain management, in pursuit of transformational impact on patients’ lives. For more information, visit the company’s website at www.zyus.com.

To schedule a one-on-one meeting, please contact your ROTH MKM representative.

To view IBN’s coverage of the conference, visit https://ibn.fm/Roth2024

About IBN’s Coverage

IBN, a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the companies participating at 36th Annual Roth Conference. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.

For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Corporate Communications
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com